BREAKING NEWS

Study shows improved performance for FluMist quadrivalent vaccine
Patients take oral GLP-1 analogue as a single daily tablet
Lancet publishes meta-analysis pooling almost 120,000 patients
Two out of three women achieve a clinical response
Nearly 68% of patients treated with AR101 could tolerate peanut protein
Tablets are also indicated to treat drug-induced extrapyramidal reactions
But lawmakers are far from united on the issue
New CEO believes “breakthrough innovations” are key to future growth
Law journal article considers the strategy’s legal and ethical implications
First treatment for patients with inoperable tumors after chemoradiation

P&T February 2018
Table of Contents

Features

CMS Could Move in That Direction for Marketplace Plans After 2019, but the Discussion Has Already Started
A proposed CMS rule promising to consider a federal default prescription drug benefit after 2019 has startled manufacturers, pharmacy benefit managers, P&T committees, and pharmacies alike. We consider the rationale and potential effects of such a rule.
The authors review the pathophysiology, etiology, screening, and diagnosis of osteoporosis; selected professional guidelines and recommendations; nonpharmacological management; pharmacological options; and the cost-effectiveness of those options.
Through a retrospective review, the authors found that a pharmacy-led medication reconciliation program in a community hospital decreased the number of significant, serious, and life-threatening medication reconciliation errors upon patient admission.
Meeting Highlights
We review key sessions on Hodgkin’s lymphoma, diffuse large B-cell lymphoma, thromboembolism, hemophilia, sickle cell disease, and chronic lymphocytic leukemia.
Pipeline Plus
Upcoming antibacterial agents in the pipeline appear promising, but it is difficult to predict their long-term durability. This article focuses on investigational agents that target resistant gram-negative organisms commonly found in the health care setting.

Departments

Medication Errors
The absence of a drug–disease interaction alert leads to a child’s death
Prescription: Washington
CMS considering pharmacy counter discounts for Part D drugs in the future
Approvals, new indications, regulatory activities, and more
Benznidazole for pediatric patients with Chagas disease; vestronidase alfa-vjbk (Mepsevii) for adults and children with mucopolysaccharidosis type VII; and hepatitis B vaccine (recombinant), adjuvanted (Heplisav-B), for the prevention of infection caused by all known subtypes of hepatitis B virus in adults
Drug Forecast
Betrixaban (Bevyxxa): a direct-acting oral anti-coagulant factor Xa inhibitor